-
ʻO Ruxolitinib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) ʻO Ruxolitinib Myelofibrosis Novartis Iulai 6, 2024 -
Crisaborole
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Crisaborole ʻO ka Dermatitis Atopic a me ka Eczema Pfizer Iune 11, 2026 -
Vericiguat
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Vericiguat Puuwai poho Bayer a me MSD Mei.24, 2031 -
Abrocitinib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Abrocitinib ʻO ka Dermatitis Atopic Pfizer Feb.11, 2034 -
Rimegepant
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Rimegepant ʻO ka migraine headache Biohaven Feb. 22, 2031 -
Elagolix 834153-87-6
Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP ElagolixCAS:834153-87-6 Endometriosis I-Hale -
Relugolix 737789-87-6
Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP Ribociclib CAS: 737789-87-6 Atineoplastic I-Hale -
Venetoclax 1257044-40-8
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031 -
Velpatasvir(PVP)
Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP Velpatasvir(PVP) HCV I-Hale √ -
ʻO Thalidomide
Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP ʻO Thalidomide Laʻau oncology USP/EP -
Ticagrelor
Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP Ticagrelor ʻAiʻaʻa I-Hale 28984 √